Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Brand name
•Nexavar
Recommended by FDA
•Yes
Chemical Formula
• C21H16ClF3N4O3
Metabolism
• Metabolized primarily in the liver
Nexavar is used to treat
Liver cancer (hepatocellular
carcinoma)
Thyroid cancer
A type of kidney cancer called
advanced...
Haemorrhage (incl. gastrointestinal,
respiratory tract, cerebral)
Hypertension
Diarrhoea
Nausea
Vomiting
Rash
Fatig...
 Leucopenia
 Neutropenia
 Anaemia
 Thrombocytopenia
 Anorexia
 Hypocalcaemia
 Depression
 Congestive heart
failure...
 Hypersensitivity
reactions (including
skin reactions and
urticaria)
 Hypothyroidism
 Hyperthyroidism
 Dehydration
 A...
Recommended Daily Dose
 Nexavar should be taken
without food or together
with a low- or moderate-fat
meal.
 Patients who...
Levels of sorafenib may be
increased in patients with
severe hepatic impairment.
Nexavar is not recommended for use in
 Pregnant women
 Women who are breastfeeding.
 Children and adolescents (<18 year...
Treatment should continue as long
as clinical benefit is observed or
until unacceptable toxicity occurs.
 Sorafenib is a multi-kinase inhibitor
 Small molecular inhibitor of
 Raf kinase
 PDGF (platelet-derived growth factor...
 Preclinical studies suggest that sorafenib
acts on tumors and tumor vasculature
By inhibiting cellular proliferation and...
Sorafenib induces apoptosis
Primarily by down-regulation of the
anti apoptotic protein Mcl-1 by a
MEK/ERK-independent mec...
In a study of 602 people
Nexavar helped slow cancer growth
and extend the lives of patients
compared with patients who d...
Nexavar (Sorafenib)
Nexavar (Sorafenib)
Nexavar (Sorafenib)
Upcoming SlideShare
Loading in …5
×

Nexavar (Sorafenib)

Nexavar (Sorafenib)

  • Login to see the comments

Nexavar (Sorafenib)

  1. 1. Brand name •Nexavar Recommended by FDA •Yes
  2. 2. Chemical Formula • C21H16ClF3N4O3 Metabolism • Metabolized primarily in the liver
  3. 3. Nexavar is used to treat Liver cancer (hepatocellular carcinoma) Thyroid cancer A type of kidney cancer called advanced renal cell carcinoma
  4. 4. Haemorrhage (incl. gastrointestinal, respiratory tract, cerebral) Hypertension Diarrhoea Nausea Vomiting Rash Fatigue pain (mouth, abdominal, bone, tumour, headache) Increased amylase and lipase
  5. 5.  Leucopenia  Neutropenia  Anaemia  Thrombocytopenia  Anorexia  Hypocalcaemia  Depression  Congestive heart failure  Myocardial ischemia and infarction  Hoarseness  Constipation  Stomatitis (including dry mouth and glossodynia)  Dry skin  Acne  Renal failure  Fever  Influenza like illness  Weight decrease
  6. 6.  Hypersensitivity reactions (including skin reactions and urticaria)  Hypothyroidism  Hyperthyroidism  Dehydration  Acute respiratory distress, etc)  Gastro oesophageal reflux disease  Pancreatitis  Gastritis  Increase in bilirubin  Jaundice  Eczema  Keratoacanthoma / squamous cell cancer of the skin
  7. 7. Recommended Daily Dose  Nexavar should be taken without food or together with a low- or moderate-fat meal.  Patients who intend to have a high-fat meal should take Nexavar at least 1 hour before or 2 hours after the meal.  The tablets should be taken with a glass of water.  400 mg (2 x 200 mg tablets) twice daily
  8. 8. Levels of sorafenib may be increased in patients with severe hepatic impairment.
  9. 9. Nexavar is not recommended for use in  Pregnant women  Women who are breastfeeding.  Children and adolescents (<18 years) due to lack of data.  Temporary interruption of sorafenib therapy is recommended in patients undergoing major surgical procedures.
  10. 10. Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.
  11. 11.  Sorafenib is a multi-kinase inhibitor  Small molecular inhibitor of  Raf kinase  PDGF (platelet-derived growth factor)  VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor  Simultaneously targets Raf/Mek/Erk pathway
  12. 12.  Preclinical studies suggest that sorafenib acts on tumors and tumor vasculature By inhibiting cellular proliferation and angiogenesis and/or By inducing apoptosis  In most tumor types, sorafenib inhibited signaling through Raf  As evidenced by reduced pERK levels
  13. 13. Sorafenib induces apoptosis Primarily by down-regulation of the anti apoptotic protein Mcl-1 by a MEK/ERK-independent mechanism
  14. 14. In a study of 602 people Nexavar helped slow cancer growth and extend the lives of patients compared with patients who did not receive Nexavar Nexavar extended overall survival by 44%.

×